Essais liés9clinical trials
VillePozuelo de Alarcónlocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT04544436

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Giredestrant Cancer Phase 3 NCT06065748 A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) ACTIVE_NOT_RECRUITING
Prasinezumab Parkinson Phase 2 NCT04777331 PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT04544436 MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING
Trontinemab Alzheimer Phase 3 NCT07169578 TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease RECRUITING
Prasinezumab Parkinson Phase 3 NCT07174310 PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease RECRUITING
RO7269162 Alzheimer Phase 2 NCT06402838 A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT04548999 GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) ACTIVE_NOT_RECRUITING
Fenebrutinib SEP Phase 3 NCT04586010 FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING
Fenebrutinib SEP Phase 3 NCT04544449 FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis ACTIVE_NOT_RECRUITING